AbbVie Reports Promising Mid-Stage Trial Data for Blood-Cancer Treatment
April 12 2022 - 8:56AM
Dow Jones News
By Rob Curran
Drugmaker AbbVie Inc. reported what it said is promising data
from a mid-stage trial of an oncology treatment in blood-cancer
patients.
AbbVie's navitoclax drug candidate was administered in
combination with ruxolitinib to 34 patients with a rare blood
cancer called myelofibrosis. The trial suggested the treatment may
reverse the bone marrow fibrosis caused by the cancer, and could
extend survival for patients who respond to the drugs, AbbVie
said.
Myelofibrosis is a blood cancer that originates in the bone
marrow, leading to fibrosis.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
April 12, 2022 08:41 ET (12:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2024 to Aug 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2023 to Aug 2024
